Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27566665 | 0.86 | LTA4H (0.47) | SMN1; SMN2LTA4HEPHX2 | |
| SCHEMBL3329127 | 0.84 | CES2 (0.52) | ALOX5 | |
| Hydrochloric Acid SCHEMBL5613814 | 0.83 | CES2 (0.50) | ALOX5 | |
| SCHEMBL10048247 | 0.80 | SMN1; SMN2 (0.66) | SRD5A2NPY5RNR3C1SMN1; SMN2FFAR1 | |
| SCHEMBL7563153 | 0.79 | SRD5A2 (0.55) | SRD5A2NPY5RNR3C1SMN1; SMN2FFAR1 | |
| SCHEMBL28159713 | 0.78 | SRD5A2 (0.63) | SRD5A2NR3C1FFAR1LTA4HEPHX2 | |
| SCHEMBL1594428 | 0.78 | SRD5A2 (0.58) | SRD5A2NR3C1FFAR1LTA4HEPHX2 | |
| SCHEMBL9711189 | 0.78 | SRD5A2 (0.62) | SRD5A2NPY5RNR3C1FFAR1LTA4H | |
| SCHEMBL850542 | 0.78 | SRD5A2 (0.62) | SRD5A2NPY5RNR3C1FFAR1LTA4H | |
| SCHEMBL1145770 | 0.77 | SRD5A2 (0.83) | SRD5A2NR3C1FFAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | SRD5A2 1080/4885NPY5R 391/4885NR3C1 1464/4885 |
| US-20060058374-A1 | Urotensin II receptor agents | UTS2R, PLAUR, SCTR | SRD5A2 1167/4885NPY5R 379/4885NR3C1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.